Richard is the Founder and Director of RosettaPath, a science-based pathology consultancy providing research and toxicologic pathology expertise for biotech, pharmaceutical, contract research organisations and software vendors. He has a keen interest in assessing the translational relevance and predictivity of nonclinical models for both efficacy and safety endpoints to enable effective decision making within medicine development projects. He has developed expertise in contributing to weight of evidence documents to assess the human carcinogenic potential of pharmaceuticals as enabled by ICHS1B (R1). Richard was formerly Chair of the Non Clinical Carcinogenicity Panel with GSK and also has contributed as a Member of the Committee On Carcinogenicity Of Chemicals In Food, Consumer Products And The Environment (COC). This committee advises the UK government and government agencies on whether substances are likely to cause cancer. Prior to RosettaPath, Richard led the Global Pathology team within Clinical Pharmacology & Safety Sciences at AstraZeneca which provides pathology expertise to assess nonclinical efficacy and safety of projects across a range of therapeutic modalities and diverse disease indications. Richard qualified in Veterinary medicine from the University of Cambridge, completed a DPhil at Oxford in experimental pathology and immunology, was Head of the UK Pathology department at GSK from 2014 to 2022 and is board certified in pathology (FRCPath, DipECVP) and toxicology (DABT). He is a Fellow of the International Academy of Toxicologic Pathology.